Cancer
Follicular lymphoma is an incurable type of non-Hodgkin lymphoma. Due to the heterogeneity of the disease, it can be challenging to assign treatment at diagnosis. Disease course also varies significantly from patient to patient. Nearly all patients experience relapse, with many experiencing multiple relapses over the course of their disease. The impact of multiple courses of treatment and the understanding that there is currently no cure for FL can take a significant toll on the physical and psychological well-being of patients.
Since 2021, the Follicular Lymphoma Foundation (FLF) has partnered with SPARC to assess the follicular lymphoma therapeutic development landscape and identify priority areas for funding to accelerate meaningful therapeutic development.
SPARC developed a request for proposals in collaboration with FLF, and managed cycle 1 grantees, accounting for $1.9 million in funding. During the next funding cycle, SPARC supported the FLF as they navigated a co-funding partnership. The result of this collaboration was $2.25 million in funding for follicular lymphoma research.
In 2023, SPARC assessed the therapeutic development and clinical landscapes in follicular lymphoma. The resulting report reflects these findings and priorities for therapeutic modalities with the greatest potential for impact in follicular lymphoma and opportunities for strategic investments in this space.
Childhood brain cancers are among the rarest and most difficult to treat, but new models of collaboration are changing what’s possible. This article explores how philanthropy, advocacy, and cross-sector partnerships are breaking down barriers and accelerating progress toward better treatments.
Collaboration and community are vital in tackling rare diseases like sarcoidosis. This piece highlights how new initiatives are connecting researchers, patients, and funders to drive progress.
The Follicular Lymphoma Foundation has launched the CURE FL Awards, a new grant program managed by Milken Institute’s Center for Strategic Philanthropy.